On the one hand, QUE significantly increases the sensitivity of pancreatic cancer and hepatocellular carcinoma cells to gemcitabine and DOX by decreasing hypoxia-inducible factor-1α (HIF-1α) expression and inhibiting P-gp [135]. The gene discussed is PGP; the disease is hepatocellular carcinoma.